- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of August 6
The Center for Biosimilars® recaps the top 5 articles for the week of August 6, 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of August 6.
Number 5: Stada recently announced that it is increasing its presence in the biosimilar sphere by becoming the majority shareholder in Bioceuticals, a venture capital-funded organization created by Stada to carry out its biosimilar programs.
Number 4: Full results of a 30-week study of Pfizer’s biosimilar infliximab, Ixifi, in patients with rheumatoid arthritis show the product has similar efficacy to Remicade, with or without dose escalation.
Number 3: The United Kingdom has proposed extending price controls to biosimilars. The measures require brand-name drug makers to pay the government 7.8% of their sales of products to the National Health Service.
Number 2: The Initiative for Medicines, Access, and Knowledge has issued a new report that calls out drug makers for securing large numbers of patents—and raising prices—on high-cost drugs.
Number 1: Celltrion’s troubled manufacturing plant is the subject of yet another FDA Form 483.
Finally, last week, our e-newsletter asked whether Congress should pass newly introduced legislation requiring innovator and biosimilar sponsors to disclose the terms of agreements that delay biosimilar market entry.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
